Pages
- About us
- Accueil
- All events
- Commercial Manufacturing
- Confidentiality Policy
- Contact & Quotation Request
- Contact the Personal Data Protection Officer
- Cosmetic Peptides
- COVID-19 Information
- Custom R&D
- Generic peptides
- Individualized Peptides
- Investors
- New Products
- News
- Newsletter
- Oligo
- Oligos
- Our Stories
- Personal data
- Quality at PolyPeptide
- Request our Documentation
- Scale and Synthesis strategy
- Search Result
- Services
- Subscribe to PolyPeptide Newsletter
Posts by category
- Category: Ad hoc announcements pursuant to Art. 53 LR
- PolyPeptide achieves strong profitable growth in 2021
- PolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen
- Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG
- PolyPeptide reports strong H1 2021 revenue growth and operating leverage amidst favorable market environment and encouraging business trends
- PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee
- PolyPeptide Group announces the exercise of the full over-allotment option
- Category: Business news
- PolyPeptide wins Malmö Life Science Business Award
- Efficient and sustainable solutions for large scale peptide manufacturing
- Proclamation honoring Jane Salik upon her retirement
- Stock Exchange Listing
- PolyPeptide News Flash, #1, 2021
- Therapeutic Indications for the PolyPeptide Group Pipeline Projects 2020
- New In-Silico Development Tools Support More Efficient Process Design
- PolyPeptide News Flash, #3, 2020
- Capacity Expansion through Investment and Innovation
- PolyPeptide News Flash, #2, 2020
- Information Letter on COVID-19
- New member of the Medicon Valley Alliance
- PolyPeptide News Flash February 2020
- Innovation and Technology
- PolyPeptide News Flash October
- Press release: the start of a research collaboration program with IBMM in Montpellier, France
- Symposium on Preparative and Process Scale HPLC, MCC and SFC 2019
- Book your meeting with PolyPeptide at CPhI worldwide – Frankfurt, Germany 5-7 November 2019
- 100% Sustainable energy from wind turbines at PolyPeptide Sweden
- PolyPeptide attends TIDES Europe – Amsterdam, November 7th and 8th
- Category: Media releases
- Monika Casanova joining PolyPeptide as CHRO and member of the PMC
- PolyPeptide announces results of the annual General Meeting 2022
- PolyPeptide publishes invitation to the annual General Meeting 2022
- PolyPeptide customer Cara Therapeutics with FDA approval for novel treatment of moderate-to-severe pruritus in hemodialysis patients
- PolyPeptide Group appoints Raymond De Vré as new Chief Executive Officer
- PolyPeptide Group Selected by Novavax to Manufacture Critical Intermediates of Matrix-M™ Adjuvant for its COVID-19 Vaccine
Generic peptides
- Semaglutide
- Triptorelin
- Somatostatin
- PTH (1-34) Teriparatide
- Octreotide
- Liraglutide
- Leuprolide
- Felypressin
- Desmopressin
- Deslorelin
- Calcitonin
- Atosiban
- Vasopressin, 8-L-Arginine
- Exenatide
- Carbetocin
- ACTH (1-39) Porcine
Events
- Half year results conference 2022 at 09:30am
- European Peptide Symposium
- IOPC: International Oligonucleotides and Peptides Conference
- BIO International Convention
- Full year results 2022
- Baader Swiss Equities Conference, digital
- Octavian Seminar, Flims, CH
- FY 2021 Results
- FY2021 Results conference
- Last trading day incl. dividend entitlement
- Dividend ex-date
- Dividend record date
- Dividend payment date
- Half year results 2022 at 07:00am
- 2021 Half-Year Results
- Morgan Stanley 19th Annual Global Healthcare Conference
- ZKB Swiss Equities Conference
- 14th Credit Suisse Equity Forum Switzerland
- Berenberg Swiss Seminar, digital
- General Meeting 2023
- General Meeting 2022